eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2024
vol. 23
 
Share:
Send email
Share:
abstract:
Original paper

The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer

Edyta Leśniak
1
,
Emilia Stec-Martyna
2
,
Daria Domańska-Senderowska
3
,
Hanna Romanowicz
4
,
Tomasz Krawczyk
4
,
Jan Bieńkiewicz
1
,
Andrzej Malinowski
1
,
Miłosz Wilczyński
5, 6

  1. Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  2. Central Scientific Laboratory CoreLab, Medical University of Lodz, Lodz, Poland
  3. Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland
  4. Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  5. Department of Surgical and Endoscopic Gynecology, Medical University of Lodz, Lodz,
  6. Department of Surgical, Endoscopic and Gynecological Oncology, Polish Mother’s Health Center-Research Institute, Lodz, Poland
Menopause Rev 2024; 23(4): 180-184
DOI: https://doi.org/10.5114/pm.2024.145949
Online publish date: 2024/12/22
View full text Get citation
 
PlumX metrics:
Introduction:
Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.

Material and methods:
Healthy controls and patients with high-grade serous carcinoma (n = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.

Results:
The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (p < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.

Conclusions:
This study supports the critical role of microRNA-196a in the progression of ovarian cancer.

keywords:

biomarkers, polymorphisms, ovarian cancer, miRNA, oncogenesis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.